We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

65 hedge funds and large institutions have $953M invested in China Biologic Products Holdings, Inc. in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 15

32% more capital invested

Capital invested by funds: $724M → $953M (+$229M)

20% more funds holding

Funds holding: 5465 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

80% less call options, than puts

Call options by funds: $807K | Put options by funds: $4.05M

Holders
65
Holders Change
+11
Holders Change %
+20.37%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
27
Reduced
15
Closed
5
Calls
$807K
Puts
$4.05M
Net Calls
-$3.24M
Net Calls Change
-$2.44M
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$2.67M +$1.84M +29,727 +299%
Two Sigma Investments
27
Two Sigma Investments
New York
$2.5M +$417K +6,725 +22%
BIM
28
Bogle Investment Management
Massachusetts
$2.42M +$524K +8,461 +31%
SIM
29
Spark Investment Management
New York
$2.2M +$616K +9,941 +43%
MAA
30
Managed Account Advisors
New Jersey
$2.07M +$233K +3,756 +14%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$1.99M -$538K -8,680 -23%
BA
32
BlackRock Advisors
Delaware
$1.97M -$602K -9,720 -25%
Citadel Advisors
33
Citadel Advisors
Florida
$1.58M +$733K +11,835 +102%
GCP
34
GSA Capital Partners
United Kingdom
$1.51M +$24.8K +400 +2%
ACM
35
Ativo Capital Management
Illinois
$1.5M +$74.7K +1,206 +6%
Ninety One (UK)
36
Ninety One (UK)
United Kingdom
$1.44M +$1.33M +21,409 New
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.29M +$86.8K +1,400 +8%
NONA
38
Ninety One North America
New York
$1.26M +$1.16M +18,787 New
EI
39
EAM Investors
California
$1.02M -$143K -2,305 -13%
BG
40
BlackRock Group
United Kingdom
$851K -$350K -5,646 -31%
NA
41
Navellier & Associates
Nevada
$750K +$691K +11,149 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$745K +$687K +11,081 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$706K +$651K +10,508 New
RFC
44
Russell Frank Company
Washington
$649K -$160K -2,588 -21%
PP
45
PDT Partners
New York
$558K +$62.9K +1,015 +14%
Geode Capital Management
46
Geode Capital Management
Massachusetts
$472K +$104K +1,674 +31%
CS
47
Credit Suisse
Switzerland
$471K -$89.2K -1,440 -17%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$430K -$273K -4,400 -41%
BPGAM
49
BTG Pactual Global Asset Management
Bermuda
$381K +$31K +500 +10%
AAMU
50
Amundi Asset Management US
Massachusetts
$371K +$342K +5,525 New

CBPO Hedge Fund Activity: Q4 2014 in Review

65 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2014, worth a combined $953M — up 32% from $724M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CBPO positions and 5 closed out — a net gain of 12 holders — while 27 added to existing stakes and 15 trimmed.

The largest buyer was Matthews International Capital Management, opening a new position worth an estimated $9.53M. The largest seller was Invesco, cutting an estimated $1.11M.

  • 65 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2014, up from 54 in Q3 2014.
  • Funds reported $953M of China Biologic Products Holdings, Inc. stock for Q4 2014, up 32% quarter-over-quarter.
  • 17 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2014 and 5 closed out, a net change of +12 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q4 2014 was Matthews International Capital Management, an estimated $9.53M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q4 2014 was Invesco, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2014.